UA80114C2 - Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one and derivatives - Google Patents
Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one and derivatives Download PDFInfo
- Publication number
- UA80114C2 UA80114C2 UA20040907250A UA20040907250A UA80114C2 UA 80114 C2 UA80114 C2 UA 80114C2 UA 20040907250 A UA20040907250 A UA 20040907250A UA 20040907250 A UA20040907250 A UA 20040907250A UA 80114 C2 UA80114 C2 UA 80114C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formula
- methyl
- tetrahydro
- pyrido
- pyrimidin
- Prior art date
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000002081 enamines Chemical class 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 19
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000000543 intermediate Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical group [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910000085 borane Inorganic materials 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 239000012048 reactive intermediate Substances 0.000 claims 2
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- UHCNJWDXFDOOIK-UHFFFAOYSA-N 2-(2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-3-yl)acetaldehyde Chemical compound C1CCCC2=NC(C)=C(CC=O)CN21 UHCNJWDXFDOOIK-UHFFFAOYSA-N 0.000 abstract 1
- CUGQZZRKQPRHGT-UHFFFAOYSA-N 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethenyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)C=CC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 CUGQZZRKQPRHGT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- -1 sodium trisacetoxyborohydride Chemical compound 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000005605 benzo group Chemical group 0.000 description 4
- 238000009835 boiling Methods 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- CGKRFDXHYBJWPO-UHFFFAOYSA-N C(C)[AlH]CC.[Na] Chemical compound C(C)[AlH]CC.[Na] CGKRFDXHYBJWPO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000013447 Xanthosoma atrovirens Nutrition 0.000 description 1
- 240000001781 Xanthosoma sagittifolium Species 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000012988 high-throughput synthesis Methods 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- RYGUCYSSMOFTSH-UHFFFAOYSA-N oxane-4-carbonyl chloride Chemical group ClC(=O)C1CCOCC1 RYGUCYSSMOFTSH-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200200531A ES2197801B1 (es) | 2002-03-05 | 2002-03-05 | Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona. |
| PCT/EP2003/002157 WO2003074522A1 (en) | 2002-03-05 | 2003-03-03 | Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80114C2 true UA80114C2 (en) | 2007-08-27 |
Family
ID=27772022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040907250A UA80114C2 (en) | 2002-03-05 | 2003-03-03 | Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one and derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7205405B2 (xx) |
| EP (1) | EP1480978A1 (xx) |
| JP (1) | JP2005525366A (xx) |
| KR (1) | KR100680003B1 (xx) |
| CN (1) | CN1315826C (xx) |
| AU (1) | AU2003219010A1 (xx) |
| BR (1) | BR0308139A (xx) |
| CA (1) | CA2474811A1 (xx) |
| CO (1) | CO5611140A2 (xx) |
| CR (1) | CR7462A (xx) |
| ES (1) | ES2197801B1 (xx) |
| IL (1) | IL163750A0 (xx) |
| MA (1) | MA26353A1 (xx) |
| MX (1) | MXPA04008289A (xx) |
| NO (1) | NO20043447L (xx) |
| NZ (1) | NZ534463A (xx) |
| PL (1) | PL370502A1 (xx) |
| RU (1) | RU2272037C9 (xx) |
| TN (1) | TNSN04139A1 (xx) |
| UA (1) | UA80114C2 (xx) |
| WO (1) | WO2003074522A1 (xx) |
| ZA (1) | ZA200405939B (xx) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1453521B1 (en) * | 2001-12-05 | 2013-09-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| KR20040025224A (ko) * | 2002-09-18 | 2004-03-24 | 주식회사 대웅 | 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| CA2000786C (en) * | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| GB9008850D0 (en) * | 1990-04-19 | 1990-06-13 | Janssen Pharmaceutica Nv | Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones |
| EP1280804B1 (en) * | 2000-05-05 | 2004-04-14 | RPG Life Sciences Limited | A process for the preparation of anti-psychotic 3- 2- 4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido 1,2,-a]pyrimidin-4-one |
-
2002
- 2002-03-05 ES ES200200531A patent/ES2197801B1/es not_active Expired - Fee Related
-
2003
- 2003-03-03 WO PCT/EP2003/002157 patent/WO2003074522A1/en active Application Filing
- 2003-03-03 PL PL03370502A patent/PL370502A1/xx not_active Application Discontinuation
- 2003-03-03 AU AU2003219010A patent/AU2003219010A1/en not_active Abandoned
- 2003-03-03 NZ NZ534463A patent/NZ534463A/en unknown
- 2003-03-03 US US10/503,478 patent/US7205405B2/en not_active Expired - Fee Related
- 2003-03-03 MX MXPA04008289A patent/MXPA04008289A/es active IP Right Grant
- 2003-03-03 RU RU2004129763/04A patent/RU2272037C9/ru not_active IP Right Cessation
- 2003-03-03 UA UA20040907250A patent/UA80114C2/uk unknown
- 2003-03-03 EP EP03714770A patent/EP1480978A1/en not_active Withdrawn
- 2003-03-03 BR BR0308139-7A patent/BR0308139A/pt not_active IP Right Cessation
- 2003-03-03 CA CA002474811A patent/CA2474811A1/en not_active Abandoned
- 2003-03-03 KR KR1020047013537A patent/KR100680003B1/ko not_active IP Right Cessation
- 2003-03-03 CN CNB038044870A patent/CN1315826C/zh not_active Expired - Fee Related
- 2003-03-03 JP JP2003572990A patent/JP2005525366A/ja active Pending
- 2003-03-03 IL IL16375003A patent/IL163750A0/xx unknown
-
2004
- 2004-07-26 ZA ZA200405939A patent/ZA200405939B/en unknown
- 2004-07-27 MA MA27800A patent/MA26353A1/fr unknown
- 2004-07-29 TN TNP2004000139A patent/TNSN04139A1/en unknown
- 2004-08-18 NO NO20043447A patent/NO20043447L/no not_active Application Discontinuation
- 2004-08-31 CO CO04085289A patent/CO5611140A2/es not_active Application Discontinuation
- 2004-09-03 CR CR7462A patent/CR7462A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2474811A1 (en) | 2003-09-12 |
| ZA200405939B (en) | 2006-06-28 |
| PL370502A1 (en) | 2005-05-30 |
| CN1639163A (zh) | 2005-07-13 |
| TNSN04139A1 (en) | 2007-03-12 |
| WO2003074522A1 (en) | 2003-09-12 |
| CN1315826C (zh) | 2007-05-16 |
| IL163750A0 (en) | 2005-12-18 |
| RU2272037C1 (ru) | 2006-03-20 |
| KR100680003B1 (ko) | 2007-02-08 |
| NZ534463A (en) | 2006-02-24 |
| CR7462A (es) | 2005-02-10 |
| JP2005525366A (ja) | 2005-08-25 |
| MXPA04008289A (es) | 2004-11-26 |
| KR20040091679A (ko) | 2004-10-28 |
| CO5611140A2 (es) | 2006-02-28 |
| AU2003219010A1 (en) | 2003-09-16 |
| MA26353A1 (fr) | 2004-10-01 |
| ES2197801A1 (es) | 2004-01-01 |
| US7205405B2 (en) | 2007-04-17 |
| NO20043447L (no) | 2004-08-18 |
| EP1480978A1 (en) | 2004-12-01 |
| BR0308139A (pt) | 2005-01-04 |
| ES2197801B1 (es) | 2005-03-16 |
| US20050143395A1 (en) | 2005-06-30 |
| RU2272037C9 (ru) | 2006-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6148594B2 (ja) | Ｅ１活性化酵素阻害剤の合成のためのプロセス | |
| MX2011006442A (es) | Compuestos de purina. | |
| EP1805179A2 (en) | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | |
| CN108368111B (zh) | 吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体 | |
| KR102073181B1 (ko) | 광학적으로 순수하고 임의로 치환된 2-(1-히드록시-알킬)-크로멘-4-온 유도체의 제조방법 및 약제 제조에 있어서의 그의 용도 | |
| HUE024989T2 (en) | Azaindole derivatives as ABI and SRC protein kinase inhibitors | |
| Yadav et al. | Synthesis of β-carboline-fused 1, 4-oxazepines and their assessment as antiplasmodial agents | |
| CA2813144C (en) | Chromene derivatives | |
| UA80114C2 (en) | Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one and derivatives | |
| CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
| KR101867988B1 (ko) | 팔리페리돈 중간체 및 이를 이용한 팔리페리돈의 제조방법 | |
| CN108290859B (zh) | 喹啉衍生物的盐型、晶型及其制备方法和中间体 | |
| JPH0269476A (ja) | ピリミジン誘導体の製法 | |
| CA3117113A1 (en) | 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof | |
| KR102188341B1 (ko) | 아픽사반의 제조방법 | |
| PT1461338E (pt) | Processo melhorado para a preparação de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)-1-piperidinil)etil)-6,7,8,9-tetra-hidro-2-metil-4h-pirido [1,2-a] pirimidin-4-ona | |
| Batra et al. | Chemistry of 5 (2H)‐isoxazolones: Novel conversion of positional isomers | |
| Sinha et al. | A novel and unusual method for C–N bond formation in 1-substituted-pyrrolidin-2-ones | |
| JP6997769B2 (ja) | ２－（６－ニトロピリジン－３－イル）－９Ｈ－ジピリド［２，３－ｂ；３’，４’－ｄ］ピロールの製造方法 | |
| Plisson et al. | Synthesis of substituted pyrimido [4, 5‐b] and [5, 4‐c]‐[1, 8] naphthyridines | |
| Bodtke et al. | Synthesis of 2-oxo-2, 3, 5, 6-tetrahydro-5-thioxoimidazo [1, 2-c] quinazolines by one-pot cyclization of α-aminocarboxylic esters with 2-(isothiocyanato) benzonitrile (ITCB) | |
| WO2024086569A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| JPH0269469A (ja) | ジヒドロフラン誘導体及びその製法 | |
| Štefanič et al. | A synthesis of alkyl 4-alkyl-2-hydroxy-3-oxo-3, 4-dihydro-2H-1, 4-benzoxazine-2-carboxylates | |
| CN105085515B (zh) | 作为凝血因子Xa抑制剂的酰肼类化合物 |